Comments on: FDA Tysabri Panel Violates New Conflict Rule http://www.pharmalot.com/2007/07/fda-tysabri-panel-violates-new-conflict-rule/ News, Comment and Conversation Fri, 10 Feb 2012 22:21:39 +0000 http://wordpress.org/?v=2.6.2 By: Tony F http://www.pharmalot.com/2007/07/fda-tysabri-panel-violates-new-conflict-rule/#comment-15928 Tony F Sat, 28 Jul 2007 15:53:14 +0000 http://www.pharmalot.com/2007/07/fda-tysabri-panel-violates-new-conflict-rule/#comment-15928 You deserve more than an afternoon to relax and fish on your excellent and continuing quest in exposing questionable waiver activities at the the FDA. Kudos for your work! Those interested and not familiar with another public firestorm regarding Conflict of Interests (COI) should see your column here on the continuing Provenge saga: http://www.pharmalot.com/2007/07/dendreon-provenge-and-conflicts-of-interest/ In it, you speak of Dr. Howard Scher, of NYC Sloan Kettering Cancer Hospital, and his potential COIs vs. what he reported to the FDA in his Waiver Application. Scher disclosed 2 "Grants (Related) and 1 stock COI. Net research suggests these COIs for Scher: 1. Novcea: STUDY CHAIR of DN-101; Grants & Research support 2. Medivation, Inc: PRINCIPAL INVESTIGATOR MDV3100; 3. Innovive Pharmaceuticals: PRINCIPAL INVESTIGATOR 4. Infinity Pharmaceuticals: PRINCIPAL INVESTIGATOR 5. Cougar Biotechnology: PRINCIPAL INVESTIGATOR; Advisory Board 6. Department of Defense: PRINCIPAL INVESTIGATOR PC Clinical Trials-P1 and P2 7. Bristol Myers Squibb: Consultant, Grants & Research support 8. Millennium Pharmaceuticals: Grant of Research support 9. sanofi-aventis: Grants & Research support 10. Genta: Scientific Advisory Board (as of March 6, 2007; since removed from web, but cached) 11. Biogen-Idec: Joint stock with spouse 12. Pfizer: Joint stock with spouse 13. Pharmion: Financial Conflict of Interest per Scher quote in MedPage 14. GPB Biotech: Financial Conflict of Interest per Scher quote in MedPage 15. PROQUEST INVESTMENTS: Consultant, Scientific Advisory Board; Limited Partner FINANCIAL interest Particularly noteworthy are items 1, 2 and 15 with, imo, 15 being a lotto winner.... Keep up your excellent articles in this field; I enjoy reading them immensely and appreciate the public exposure of these acts. You deserve more than an afternoon to relax and fish on your excellent and continuing quest in exposing questionable waiver activities at the the FDA. Kudos for your work!

Those interested and not familiar with another public firestorm regarding Conflict of Interests (COI) should see your column here on the continuing Provenge saga:

http://www.pharmalot.com/2007/07/dendreon-provenge-and-conflicts-of-interest/

In it, you speak of Dr. Howard Scher, of NYC Sloan Kettering Cancer Hospital, and his potential COIs vs. what he reported to the FDA in his Waiver Application. Scher disclosed 2 “Grants (Related) and 1 stock COI.

Net research suggests these COIs for Scher:

1. Novcea: STUDY CHAIR of DN-101; Grants & Research support

2. Medivation, Inc: PRINCIPAL INVESTIGATOR MDV3100;

3. Innovive Pharmaceuticals: PRINCIPAL INVESTIGATOR

4. Infinity Pharmaceuticals: PRINCIPAL INVESTIGATOR

5. Cougar Biotechnology: PRINCIPAL INVESTIGATOR; Advisory Board

6. Department of Defense: PRINCIPAL INVESTIGATOR PC Clinical Trials-P1 and P2

7. Bristol Myers Squibb: Consultant, Grants & Research support

8. Millennium Pharmaceuticals: Grant of Research support

9. sanofi-aventis: Grants & Research support

10. Genta: Scientific Advisory Board (as of March 6, 2007; since removed from web, but cached)

11. Biogen-Idec: Joint stock with spouse

12. Pfizer: Joint stock with spouse

13. Pharmion: Financial Conflict of Interest per Scher quote in MedPage

14. GPB Biotech: Financial Conflict of Interest per Scher quote in MedPage

15. PROQUEST INVESTMENTS: Consultant, Scientific Advisory Board; Limited Partner FINANCIAL interest

Particularly noteworthy are items 1, 2 and 15 with, imo, 15 being a lotto winner….

Keep up your excellent articles in this field; I enjoy reading them immensely and appreciate the public exposure of these acts.

]]>